Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01909895
Other study ID # AAAK4250
Secondary ID 1R01HL116470-01
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2013
Est. completion date November 1, 2020

Study information

Verified date January 2022
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study aims and hypotheses are as follows: Primary Hypotheses: Compared to the neutral condition, the anger recall task will acutely induce endothelial dysfunction by impairing endothelium-dependent arterial vasodilation (Hypothesis 1a); increasing circulating levels of EC-derived microparticles (EMPs), a marker of EC injury (Hypothesis 1b); and reducing circulating levels of bone marrow-derived endothelial progenitor cells (EPCs), a marker of EC reparative capacity (Hypothesis 1c). Secondary Hypotheses: Compared to the neutral condition, the depressed mood and separately the anxiety recall tasks will acutely impair endothelium-dependent arterial vasodilation, increase circulating levels of EMPs, and reduce circulating levels of bone marrow-derived EPCs. There will be a relation of the level of self-reported anger, depressed mood, and anxiety with endothelial dysfunction.


Description:

Atherosclerosis-related cardiovascular disease (CVD) events remain the leading causes of morbidity and mortality in industrialized nations. Atherosclerosis is a diffuse disease characterized by the deposition of lipid and other blood-borne material within the arterial wall. Evidence demonstrates that disruption of an arterial atherosclerotic plaque and subsequent thrombus formation is responsible for the onset of CVD events. Cardiovascular research efforts have been directed toward the identification of early underlying factors that initiate this cascade. It has been known for some time that the experience of negative emotions is associated with an increased risk of incident CVD events, independent of traditional risk factors. Among the best-studied negative emotions is anger. Population-based studies have demonstrated that the experience of anger is a trigger of incident CVD events. The mechanism(s) by which provoked anger acutely affects the pathways that underlie atherosclerosis development and progression remain to be fully characterized. Endothelial dysfunction is a promising mechanism that may explain the link between anger and incident CVD events. Vascular endothelial cells (ECs) play essential roles in maintaining vascular tone and the integrity of blood vessels. Evidence suggests that endothelial dysfunction is an early pathogenic process underlying atherosclerosis development and CVD event onset. Our preliminary findings show in apparently healthy individuals, an anger recall task acutely induces endothelial dysfunction by impairing endothelium-dependent vasodilation, injuring ECs, and disrupting the molecular processes underlying EC reparative capacity. We have additionally found that this task may induce endogenous nitric oxide (NO) inhibition, which plays a central role in aggravating endothelial dysfunction. Therefore, NO inhibition may partially mediate anger-provoked endothelial dysfunction. Although the strongest data are on anger-provoked CVD events, there is also some evidence that the experience of other core negative emotions such as depressed mood and anxiety may trigger CVD events. Whether the provocation of depressed mood and anxiety acutely induces endothelial dysfunction and NO inhibition remains to be determined. The overall aim of this study is to primarily examine the acute effects of provoked anger and secondarily depressed mood and anxiety on EC health. We will also explore whether NO inhibition partially mediates the acute effects of anger, depressed mood, and anxiety on endothelial function. Examination of these critical pathways will help identify the biological pathways by which the experience of core negative emotions leads to incident CVD risk. To address these highly significant research questions, we propose a state-of-the-art, laboratory-based, randomized controlled experiment in which 280 participants will be randomized to one of four experimental conditions: an anger recall task (N=70), a depressed mood recall task (N=70), an anxiety recall task (N=70), and an emotionally neutral condition (N=70).


Recruitment information / eligibility

Status Completed
Enrollment 280
Est. completion date November 1, 2020
Est. primary completion date November 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 and over - Fluent in English Exclusion Criteria: - History of any chronic medical condition including prevalent CVD and traditional risk factors - Active smoking - Chronic medication use, including over-the-counter drugs or herbal medications - History of psychosis, a mood disorder, or any overt personality disorder - Latex allergy - Poor peripheral veins with low possibility of getting IV access

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Anger Induction
The participant is asked to recall an incident in the recent past during which they became moderately to extremely angry, or is asked to read statements out loud evoking moderate to extreme feelings of anger. The participant is asked to take a few moments to bring the details of the incident to mind and, when ready, to describe the incident in great detail to the experimenter. Participants are asked to describe key elements, such as any dialogue that transpired during the incident, along with other details of the incident, particularly regarding the feelings of that particular emotion experienced at the time. In so doing, the experimenter works to re-elicit the emotions that accompanied the original incident. The duration of the negative emotion induction task is 8 minutes.
Depressed Mood Induction
The participant will be asked to undergo a validated depression/sadness induction task.
Anxiety Induction
The participant will be asked to undergo a validated anxiety induction task.
Neutral emotion task
This is a neutral control task that each of the negation emotion induction tasks will be compared to.

Locations

Country Name City State
United States Columbia University Medical Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
Columbia University National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Nitric oxide(NO) inhibition Circulating measures of asymmetric dimethylarginine (ADMA) and oxidative stress measures baseline; 3 mins, 40 mins, 70 mins, 100 mins after end of mood induction
Other Stress response Circulating measures of catecholamines, cortisol, endothelin-1; blood pressure and heart rate baseline; 3 mins, 40 mins, 70 mins, 100 mins after end of mood induction
Primary Endothelium-dependent arterial vasodilation baseline
Primary Circulating EMPs expressing CD62E baseline
Primary Circulating early EPCs (KDR+, CD34+, CD133+ cells) baseline
Primary Endothelium-dependent arterial vasodilation 3 mins after end of mood induction
Primary Endothelium-dependent arterial vasodilation 40 mins after end of mood induction
Primary Endothelium-dependent arterial vasodilation 70 mins after end of mood induction
Primary Endothelium-dependent arterial vasodilation 100 mins after end of mood induction
Primary Circulating EMPs expressing CD62E 3 mins after end of mood induction
Primary Circulating EMPs expressing CD62E 40 mins after end of mood induction
Primary Circulating EMPs expressing CD62E 70 mins after end of mood induction
Primary Circulating EMPs expressing CD62E 100 mins after end of mood induction
Primary Circulating early EPCs (KDR+, CD34+, CD133+ cells) 3 mins after end of mood induction
Primary Circulating early EPCs (KDR+, CD34+, CD133+ cells) 40 mins after end of mood induction
Primary Circulating early EPCs (KDR+, CD34+, CD133+ cells) 70 mins after end of mood induction
Primary Circulating early EPCs (KDR+, CD34+, CD133+ cells) 100 mins after end of mood induction
Secondary Circulating EMPs expressing CD31 baseline; 3 mins, 40 mins, 70 mins, 100 mins after end of mood induction
Secondary Circulating EMPs expressing CD51 baseline; 3 mins, 40 mins, 70 mins, 100 mins after end of mood induction
Secondary Self-reported anger, depressed mood, and anxiety baseline; 3 mins, 40 mins, 70 mins, 100 mins after end of mood induction
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT04156711 - Remote Ischemic Preconditioning in Patients Undergoing Acute Minor Abdominal Surgery N/A
Recruiting NCT06133634 - Fisetin to Improve Vascular Function in Older Adults Phase 1/Phase 2
Completed NCT05872139 - Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging N/A
Recruiting NCT04558450 - Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN) N/A
Terminated NCT03325933 - Resistance Training and Cardiometabolic Health N/A
Not yet recruiting NCT05939934 - Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal N/A
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Recruiting NCT02334839 - The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction N/A
Recruiting NCT02020044 - Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) N/A
Completed NCT01691404 - Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure (FLAVO) N/A
Completed NCT01775865 - Targeting Inflammation to Treat Cardiovascular Aging Phase 2
Terminated NCT01412216 - The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance Phase 2
Completed NCT01319344 - Effect of Eplerenone on Endothelial Function in Metabolic Syndrome Phase 3
Completed NCT00987974 - Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury Phase 4
Completed NCT00848302 - Endothelial Function in Human Arteries Early Phase 1
Completed NCT00990730 - Atherosclerosis in Rheumatoid Arthritis N/A
Completed NCT00532844 - A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction Phase 2
Completed NCT00376246 - Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects Phase 4
Completed NCT00775099 - Combustion Derived Air Pollution and Vascular Function N/A